GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adagene Inc (NAS:ADAG) » Definitions » Common Stock

ADAG (Adagene) Common Stock : $0.01 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Adagene Common Stock?

Adagene's quarterly common stock stayed the same from Dec. 2023 ($0.01 Mil) to Jun. 2024 ($0.01 Mil) and stayed the same from Jun. 2024 ($0.01 Mil) to Dec. 2024 ($0.01 Mil).

Adagene's annual common stock increased from Dec. 2022 ($0.01 Mil) to Dec. 2023 ($0.01 Mil) but then stayed the same from Dec. 2023 ($0.01 Mil) to Dec. 2024 ($0.01 Mil).

Adagene Common Stock Historical Data

The historical data trend for Adagene's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adagene Common Stock Chart

Adagene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Common Stock
Get a 7-Day Free Trial - 0.01 0.01 0.01 0.01

Adagene Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01

Adagene Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Adagene Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adagene Inc (NAS:ADAG) » Definitions » Common Stock
Comparable Companies
AVTE IGMS VERU CLSD IVVD VTGN ABOS MNOV CABA TCRX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
Xinghu Street, Suzhou Industrial Park, 4th Floor, Building C14, No. 218, Jiangsu Province, Suzhou, CHN, 215123
Website
https://www.adagene.com
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.